Katherine Neuenfeldt

Katherine Neuenfeldt

VP, Marketing

Katherine is the Vice President of Marketing at Presidio Medical. She was previously the Vice President of Market Access at Nevro, and led the Market Access and Marketing functions as Nevro grew from a small, private company to a disruptive and established player. She also led multiple high-profile product launches while at Medtronic Endovascular and previously held roles at Johnson & Johnson, HealthTech, and Triage Consulting Group. Ms. Neuenfeldt received a B.A. in Human Biology from Stanford University, a M.S. in Epidemiology from the Stanford School of Medicine, and an M.B.A. from the Darden School of Business at the University of Virginia.

Mike Faltys

Mike Faltys

VP, Implantable Systems

Mike is Vice President of Implantable Systems at Presidio Medical. He was previously CTO at the bioelectronic medicine company SetPoint Medical where he helped transform the idea of modulating the Cholinergic Inflammatory pathway into a ground-breaking Class III medical product. Starting in 1994, he architected and developed cochlear implants for Advanced Bionics from the startup stage through the acquisition by Boston Scientific. He served as the System Architect and then Vice President of R&D. At Advanced Bionics he worked with the engineers at Scond Sight, Advanced Bionics SCS, DBS, and BION programs. Mike recieved his B.S.E. from University of California, Irvine.

Andrew Sullivan

Andrew Sullivan

Chief Medical Officer

Andrew is Chief Medical Officer of Presidio Medical. Prior to Presidio, Andrew was in full-time practice as a board-certified anesthesiologist with Boulder Valley Anesthesiology as a full partner and member of the Executive Committee. During medical practice, Andrew was engaged in industry as an active consultant. He finished degrees in Biology and History, as well as his Medical Doctorate, from Indiana University. He completed his residency in Anesthesiology at the University of Colorado.

Kenneth Wu

Kenneth Wu

President & CTO

Kenneth is a co-founder and President & CTO of Presidio Medical. He was previously COO of Siris Medical, Inc an AI platform for enhancing radiation oncology treatment planning and outcomes. Prior to that, he was an R&D Program Manager at Spiracur Inc., a company focused on wound healing therapies, moving multiple products through early development to commercial release including FDA clearance and manufacturing implementation. Spiracur’s technology was acquired by Acelity L.P. He received his B.S.E. degree in mechanical and aerospace engineering from Princeton University, M.S. and Ph.D. degrees in mechanical engineering from Stanford University and is a graduate of the Stanford University Biodesign Fellowship.

Michael Onuscheck

CEO & Chairman

Michael Onuscheck will join Presidio Medical in September 2021 as CEO and Chairman after serving more than two years as an independent member of Presidio’s board.   He made his move from Alcon Inc. where he served on the Executive Committee of Alcon and the President, Global Businesses & Innovation.  Prior to that role Michael led Alcon’s Surgical products business as President & General Manager helping to turn-around and then spin Alcon out of Novartis.

Michael joined Alcon in February 2015 from Boston Scientific where he held the position of President of EMEA and Russia.  Prior to this assignment, he served as Senior Vice President and President of Boston Scientific’s Neuromodulation Division for more than seven years and was a part of the acquired of Advanced Bionics management team. Michael’s career evolved through a variety of marketing and sales management positions at Medtronic Sofamor Danek and Pfizer.

Michael earned his degree in Business Administration and Psychology from Washington and Jefferson College in Washington, Pennsylvania. 

Kenneth Wu

Kenneth Wu

President & CTO

Kenneth is a co-founder and President & CTO of Presidio Medical. He was previously COO of Siris Medical, Inc an AI platform for enhancing radiation oncology treatment planning and outcomes. Prior to that, he was an R&D Program Manager at Spiracur Inc., a company focused on wound healing therapies, moving multiple products through early development to commercial release including FDA clearance and manufacturing implementation. Spiracur’s technology was acquired by Acelity L.P. He received his B.S.E. degree in mechanical and aerospace engineering from Princeton University, M.S. and Ph.D. degrees in mechanical engineering from Stanford University and is a graduate of the Stanford University Biodesign Fellowship.

Juan Pablo Mas

Juan-Pablo Mas

Juan-Pablo is a partner at Action Potential Venture Capital based in Palo Alto, CA, and invests in start-ups that are pioneering bioelectronic medicines. He is a Board member of various companies developing therapies that leverage “electricity as medicine,” a promising alternative to traditional drug therapies. He was previously a medical device investor at Lightstone Ventures and Morgenthaler Ventures. Prior to investing, Juan-Pablo led efforts across R&D and Strategy in Medtronic’s CardioVascular Division, and subsequently served on the CV Global Brand Strategy team at Eli Lilly. Juan-Pablo earned an MBA from Stanford Graduate School of Business, an M.S. in Electrical Engineering from Stanford, and a B.S. in Electrical Engineering from the University of Massachusetts. He serves on the Oversight Committee for Stanford’s Neuroscience Institute (Wu Tsai), the Advisory Board for UCSF’s Rosenman Institute, and is a founding Board Member of LatinxVC.

Ben Tsai

Ben Tsai

Ben is a partner at Invus Opportunities, a New York based investment firm that currently manages over $1.5 billion of capital. Ben joined Invus Opportunities in 2008 when the firm spun off from sister firm The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Ben leads investments by Invus Opportunities in growing private companies and works in close partnership with market-leading management teams and investors to create lasting value. Ben has served on the Board of Directors of numerous companies, both in the healthcare sector as well as in other industries. Prior to joining Invus Opportunities, Ben was a management consultant at the Monitor Group. Ben received a B.S. in business administration from the University of Southern California and an M.B.A. from Harvard Business School.

Michael Ackermann

Michael Ackermann

Michael Ackermann is a co-founder and CEO of Presidio Medical. Michael also serves as Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST) and Chairman of Tarsus Pharmaceuticals, Inc. He was previously Vice President, Neurostimulation for Allergan, plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan. He received a B.E. degree in biomedical engineering from Vanderbilt University, M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University, is a graduate of the Stanford University Biodesign Fellowship and Vision Research Fellowship at Stanford University. He has numerous patents and peer-reviewed publications.

Michael Onuscheck

CEO & Chairman

Michael Onuscheck will join Presidio Medical in September 2021 as CEO and Chairman after serving more than two years as an independent member of Presidio’s board.   He made his move from Alcon Inc. where he served on the Executive Committee of Alcon and the President, Global Businesses & Innovation.  Prior to that role Michael led Alcon’s Surgical products business as President & General Manager helping to turn-around and then spin Alcon out of Novartis.

Michael joined Alcon in February 2015 from Boston Scientific where he held the position of President of EMEA and Russia.  Prior to this assignment, he served as Senior Vice President and President of Boston Scientific’s Neuromodulation Division for more than seven years and was a part of the acquired of Advanced Bionics management team. Michael’s career evolved through a variety of marketing and sales management positions at Medtronic Sofamor Danek and Pfizer.

Michael earned his degree in Business Administration and Psychology from Washington and Jefferson College in Washington, Pennsylvania.